ILLUCCIX

1 INDICATIONS AND USAGE ILLUCCIX, after radiolabeling with Ga 68, is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: With suspected metastasis who are candidates for initial definitive therapy With suspected recurrence based on elevated serum prostate-specific antigen (PSA) level For selection of patients who are indicated for PSMA-directed therapy as described in the prescribing information of the therapeutic products ILLUCCIX, after radiolabeling with Ga 68, is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: With suspected metastasis who are candidates for initial definitive therapy With suspected recurrence based on elevated serum prostate-specific antigen (PSA) level For selection of patients who are indicated for PSMA-directed therapy as described in the prescribing information of the therapeutic products ( 1 )

2 DOSAGE AND ADMINISTRATION Use appropriate aseptic technique and radiation safety handling measures in the manipulation and administration of Gallium Ga 68 Gozetotide Injection. ( 2.1 ) The recommended amount of radioactivity for adults is 111 MBq to 259 MBq (3 mCi to 7 mCi) as a bolus intravenous injection. ( 2.2 ) A diuretic expected to act within the uptake time period may be administered at the time of radiotracer injection. ( 2.2 ) Initiate imaging 50 minutes to 100 minutes after administration. The patient should void immediately prior to initiation of imaging. The scan should begin caudally and proceed cranially. ( 2.6 ) See full prescribing information for additional preparation, administration, imaging, and radiation dosimetry information. ( 2 ) 2.1 Radiation Safety - Drug Handling After reconstitution and radiolabeling of ILLUCCIX, the vial contains Gallium Ga 68 Gozetotide Injection. Handle Gallium Ga 68 Gozetotide Injection with appropriate safety measures to minimize radiation exposure [ see Warnings and Precautions ( 5.2 ) ]. Use waterproof gloves, effective radiation shielding, and other appropriate safety measures when preparing and handling Gallium Ga 68 Gozetotide Injection. Radiopharmaceuticals should be used by or under the control of physicians who are qualified by specific training and experience in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides. 2.2 Recommended Dosage and Administration Instructions Recommended Dosage In adults, the recommended amount of radioactivity to be administered for PET is 111 MBq to 259 MBq (3 mCi to 7 mCi) administered as an intravenous bolus injection. Administration Use aseptic technique and radiation shielding when withdrawing and administering Gallium Ga 68 Gozetotide Injection. Calculate the necessary volume to administer based on calibration time and required dose. Inspect Gallium Ga 68 Gozetotide Injection visually for particulate matter and discoloration before administration. Only use solutions that are clear, colorless or at most slightly yellow, and without visible particles. Gallium Ga 68 Gozetotide Injection may be diluted with sterile 0.9% Sodium Chloride Injection, USP. Assay the final dose in a dose calibrator immediately before administration to the patient. After injection of Gallium Ga 68 Gozetotide Injection, administer an intravenous flush of sterile 0.9% Sodium Chloride Injection, USP to ensure full delivery of the dose. Dispose of any unused drug in a safe manner in compliance with applicable regulations. Unless contraindicated, a diuretic expected to act within the uptake time period may be administered at the time of radiotracer injection to potentially decrease artifact from radiotracer accumulation in the urinary bladder and ureters. 2.3 Patient Preparation Prior to PET Imaging Instruct patients to drink a sufficient amount of water to ensure adequate hydration prior to administration of Gallium Ga 68 Gozetotide Injection and to continue to drink and void frequently following administration to reduce radiation exposure, particularly during the first hour after administration [see Warnings and Precautions ( 5.2 )] . 2.4 Drug Preparation ILLUCCIX is supplied as a 3-vial kit in two different configurations [ see Dosage Forms and Strengths (3) ] for preparation of Gallium Ga 68 Gozetotide Injection with eluate from one of the following (see below for specific instructions for use with each Ga 68 source): Cyclotron produced via GE FASTlab TM (Configuration A) Eckert & Ziegler (EZAG) GalliaPharm ® Germanium 68/Gallium 68 (Ge 68/Ga 68) generator (Configuration A) IRE Galli Eo ® Ge 68/Ga 68 generator (Configuration B) The Ge 68/Ga 68 generators and cyclotron are not supplied with ILLUCCIX. Components of ILLUCCIX include: Vial 1 (Gozetotide Vial) contains 25 mcg of gozetotide and 10 mcg of D-mannose (stabilizer) as a lyophilized powder. Vial 2 (Acetate Buffer Vial) contains 150 mg anhydrous sodium acetate in HCl buffer. Vial 3 (Sterile Vacuumed Reaction Vial) is a sterile, evacuated vial that serves as the collection vial for Ga 68 chloride and radiolabeling reaction. Prepare Gallium Ga 68 Gozetotide Injection according to the following aseptic procedure: Before use, remove the ILLUCCIX kit containing all three components from the refrigerator and allow the kit to reach room temperature for 1 hour. Use suitable shielding to reduce radiation exposure. Wear waterproof gloves. If Ga 68 is generator produced, test the Ga 68 chloride eluate for Ge 68 breakthrough weekly by a suitable method according to manufacturer recommendations. Ge 68 breakthrough and other gamma emitting radionuclides should meet the specifications (≤0.001%) provided by the manufacturer. If Ga 68 is cyclotron produced, test for Ga 66 and Ga 67 (with specification of ≤2% combined total) when a new lot of Zn 68 is introduced for manufacturing. Place a "radioactive" label on Vial 3 (Sterile Vacuumed Reaction Vial) with product name, lot number and date. Remove the vial cap from Vial 1, Vial 2 and Vial 3. Swab the top of each vial with alcohol to disinfect the surface and allow the top of each vial to dry. Note that to minimize any potential metallic contamination, the shortest possible needle should be used for the transfer of the gallium solution from the generator. The needle should be clean and dilute acid resistant. Use only plastic syringes for preparation and administration. Do not use syringes with rubber plungers. Note that prior to use of any vial, confirm the correct vial is being used by a visual check of the vial label. Follow the specific reconstitution procedure below, dependent on Ga 68 source. Then continue with the dilution and radiosynthesis procedure below. Preparation with Cyclotron Produced Ga 68 via GE FASTlab Collection of Gallium Ga 68 Chloride After purification by the FASTlab, the Ga 68 chloride solution is passed through a sterile filter and into the cassette product vial automatically by the FASTlab. Pierce Vial 3 (Sterile Vacuumed Reaction Vial) with a sterile needle connected to a 0.2 micron sterile vented filter (not supplied) to maintain atmospheric pressure within the vial during the reconstitution process. Aseptically transfer 5 mL of Ga 68 chloride solution into Vial 3. Reconstitution and Radiolabeling Reaction Procedure Insert a sterile 10 mL syringe with a needle into Vial 2 (Acetate Buffer Vial Configuration A) and draw up the contents of the vial (target 2.5 mL). Inject the contents of the 10 mL syringe into Vial 1 (Gozetotide Vial). Gently swirl Vial 1 to ensure the product is thoroughly dissolved. Insert a sterile 10 mL syringe with a needle into Vial 1 containing the dissolved gozetotide and draw up the entire contents of the vial. Transfer the contents of the 10 mL syringe to Vial 3 (Sterile Vacuumed Reaction Vial) containing the Ga 68 chloride. Wait for 5 minutes for radiolabeling to take place at ambient temperature (25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F)). Assay the whole vial containing the Gallium Ga 68 Gozetotide Injection for total radioactivity using a dose calibrator, calculate the radioactivity concentration and record the result. Perform the quality control of Gallium Ga 68 Gozetotide Injection according to the recommended methods in the Subsection 2.5 Specifications and Quality Control. Prior to use, visually inspect the solution behind a shielded screen for radioprotection purposes. Only use solutions that are clear without visible particles. Keep the vial containing the Gallium Ga 68 Gozetotide Injection upright in a radio-protective shield container at ambient temperature until use. After reconstitution and addition of Ga 68 chloride to the kit components in the reaction Vial 3, use Gallium Ga 68 Gozetotide Injection within 4 hours. The final volume of the Gallium Ga 68 Gozetotide Injection is 7.5 mL. Preparation with Eckert & Ziegler GalliaPharm Generator Collection of Gallium Ga 68 Chloride Prepare a syringe containing 5 mL of sterile ultrapure 0.1 M HCl provided with the GalliaPharm Generator for elution. Pierce Vial 3 (Sterile Vacuumed Reaction Vial) with a sterile needle connected to a 0.2 micron sterile vented filter (not supplied) to maintain atmospheric pressure within the vial during the reconstitution process. Connect the male luer of the outlet line of the GalliaPharm generator to a sterile needle. Connect Vial 3 directly to the outlet line of the GalliaPharm generator by pushing the needle through the rubber septum and place the vial in a radiation shielded container. Elute the generator directly with the 5 mL 0.1 M HCl from step 1 into Vial 3 according to the instructions for use of the GalliaPharm generator that are supplied by Eckert & Ziegler. Perform the elution manually or by means of a pump. Collect 5 mL of eluate. At the end of the elution, disconnect the generator from Vial 3 by removing the needle from the rubber septum. Reconstitution and Radiolabeling Reaction Procedure Insert a sterile 10 mL syringe with a needle into Vial 2 (Acetate Buffer Vial Configuration A) and draw up the contents of the vial (target 2.5 mL). Inject the contents of the 10 mL syringe into Vial 1 (Gozetotide Vial). Gently swirl Vial 1 to ensure the product is thoroughly dissolved. Insert a sterile 10 mL syringe with a needle into Vial 1 containing the dissolved gozetotide and draw up the entire contents of the vial. Transfer the contents of the 10 mL syringe to Vial 3 (Sterile Vacuumed Reaction Vial) containing the Ga 68 chloride. Wait for 5 minutes for radiolabeling to take place at ambient temperature (25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F)). Assay the whole vial containing the Gallium Ga 68 Gozetotide Injection for total radioactivity using a dose calibrator, calculate the radioactivity concentration and record the result. Perform the quality control of Gallium Ga 68 Gozetotide Injection according to the recommended methods in the Subsection 2.5 Specifications and Quality Control. Prior to use, visually inspect the solution behind a shielded screen for radioprotection purposes. Only use solutions that are clear without visible particles. Keep the vial containing the Gallium Ga 68 Gozetotide Injection upright in a radio-protective shield container at ambient temperature until use. After reconstitution and addition of Ga 68 chloride to the kit components in the reaction Vial 3, use Gallium Ga 68 Gozetotide Injection within 4 hours. The final volume of the Gallium Ga 68 Gozetotide Injection is 7.5 mL. Preparation with IRE Galli Eo Generator Collection of Gallium Ga 68 Chloride Connect the male luer of the outlet line of the Galli Eo generator to a sterile needle. Elute the generator directly into Vial 3 (Sterile Vacuumed Reaction Vial) according to the instructions for use of the Galli Eo generator that are supplied by IRE. Collect 1.1 mL of eluate. At the end of the elution, disconnect the generator from Vial 3 by removing the needle from the rubber septum. Reconstitution and Radiolabeling Reaction Procedure Insert a sterile 10 mL syringe with a needle into Vial 2 (Acetate Buffer Vial Configuration B) and draw up the contents of the vial (target 6.4 mL). Inject the contents of the 10 mL syringe into Vial 1 (Gozetotide Vial). Gently swirl Vial 1 to ensure the product is thoroughly dissolved. Insert a sterile 10 mL syringe with a needle into Vial 1 containing the dissolved gozetotide and draw up the entire contents of the vial. Transfer the contents of the 10 mL syringe to Vial 3 (Sterile Vacuumed Reaction Vial) containing the Ga 68 chloride. Wait for 5 minutes for radiolabeling to take place at ambient temperature (25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F)). Assay the whole vial containing the Gallium Ga 68 Gozetotide Injection for total radioactivity using a dose calibrator, calculate the radioactivity concentration and record the result. Perform the quality control of Gallium Ga 68 Gozetotide Injection according to the recommended methods in the Subsection 2.5 Specifications and Quality Control. Prior to use, visually inspect the solution behind a shielded screen for radioprotection purposes. Only use solutions that are clear without visible particles. Keep the vial containing the Gallium Ga 68 Gozetotide Injection upright in a radio-protective shield container at ambient temperature until use. After reconstitution and addition of Ga 68 chloride to the kit components in the reaction Vial 3, use Gallium Ga 68 Gozetotide Injection within 4 hours. The final volume of the Gallium Ga 68 Gozetotide Injection is 7.5 mL. Flow diagrams are provided for the radiosynthetic process to be followed at the radiopharmacy site for: ILLUCCIX Configuration "A" when using Ga 68 prepared by cyclotron ( Figure 1 ) or ILLUCCIX Configurations "A" or "B" when using an indicated GMP-grade EZAG GalliaPharm Ge 68/Ga 68 Generator ( Figure 2 ) or IRE Galli Eo Ge 68/Ga 68 Generator ( Figure 3 ). Figure 1: Preparation with Cyclotron Produced Ga 68 via GE FASTlab Note: Ga 68 from GE FASTlab is aseptically transferred into the Sterile Vacuumed Reaction Vial. Use "Configuration A" with cyclotron produced Ga 68 via GE FASTlab [ see How Supplied/Storage and Handling ( 16 )] . Figure 2: Preparation with Eckert & Ziegler GalliaPharm Generator Note: Use "Configuration A" with EZAG GalliaPharm Ge 68/Ga 68 generator [ see How Supplied/Storage and Handling ( 16 )] . Figure 3: Preparation with IRE Galli Eo Generator Note: Use "Configuration B" with IRE Galli Eo Ge 68/Ga 68 generator [ see How Supplied/Storage and Handling ( 16 )] . Figure 1 Figure 2 Figure 3 2.5 Specifications and Quality Control Perform the quality controls in Table 1 behind a lead glass shield for radioprotection purposes. Table 1: Specifications for the Radiolabeled Imaging Product (Gallium Ga 68 Gozetotide Injection) Test Analytical method Acceptance criteria Appearance Visual examination Colorless to slightly yellow solution Free from visible particles pH pH-meter or pH-strips 4.0 to 5.0 Radiochemical purity Content of gallium Ga 68 gozetotide Content of free and colloidal Ga 68 Instant thin-layer chromatography, silica gel (iTLC SG); See methods below ≥95% ≤5% Perform one of the following: Cutting Technique Pour ammonium acetate 1 M/methanol (1/1 V/V) solution to a depth of 3 mm to 4 mm in the developing chamber, cover the chamber and allow it to equilibrate. Draw a pencil line at 1 cm from the bottom of the iTLC strip, and a dotted line 5 cm from the pencil line. Apply a drop of gallium Ga 68 gozetotide at the center of the pencil line. Place the iTLC strip in the developing chamber and allow it to develop for a distance of 10 cm from the point of application. Cut the iTLC strip following the dotted line and measure each piece with the radioactivity dose calibrator. Calculate the quantity (in percent) of gallium Ga 68 gozetotide in the solution using the formula: % Gallium Ga 68 gozetotide=(Activity top piece)/(Activity bottom piece+Activity top piece) ×100 Scanning Technique Pour ammonium acetate 1 M/methanol (1/1 V/V) solution to a depth of 3 mm to 4 mm in the developing chamber, cover the chamber and allow it to equilibrate. Draw a pencil line at 1 cm from the bottom of the iTLC strip and apply a drop of gallium Ga 68 gozetotide at the center of the pencil line. Place the iTLC strip in the developing chamber and allow it to develop for a distance of 10 cm from the point of application. Scan the iTLC with a radiometric iTLC scanner. Calculate the quantity (in percent) of gallium Ga 68 gozetotide in the solution by integration of the peaks on the chromatogram. The retention factor (Rf) specifications are: Free and colloidal Ga 68 species, Rf = 0 to 0.1, Gallium Ga 68 gozetotide, Rf = 0.6 to 1. 2.6 Image Acquisition Position the patient supine with arms above the head. Begin PET scanning 50 minutes to 100 minutes after the intravenous administration of Gallium Ga 68 Gozetotide Injection. Patients should void immediately prior to image acquisition and image acquisition should begin at the proximal thighs and proceed cranially to the skull base or skull vertex. Adapt imaging technique according to the equipment used and patient characteristics in order to obtain the best image quality possible. 2.7 Image Interpretation Gallium Ga 68 gozetotide binds to PSMA. Based on the intensity of the signals, PET images obtained using gallium Ga 68 gozetotide indicate the presence of PSMA in tissues. Imaging Prior to Initial Definitive Therapy or for Biochemical Recurrence Lesions should be considered suspicious if uptake is greater than physiologic uptake in that tissue or greater than adjacent background if no physiologic uptake is expected. Tumors that do not express PSMA will not be visualized. Increased uptake in tumors is not specific for prostate cancer [ see Warnings and Precautions ( 5.1 ) ]. Imaging to Select Patients for PSMA-Directed Therapy For instructions on patient selection, refer to the prescribing information of the PSMA-directed therapeutic product. 2.8 Radiation Dosimetry Estimated radiation absorbed doses per injected activity for organs and tissues of adult male patients following an intravenous bolus of Gallium Ga 68 Gozetotide Injection are shown in Table 2 . The effective radiation dose resulting from the administration of 259 MBq (7 mCi) is about 4.4 mSv. The radiation doses for this administered dose to the critical organs, which are the kidneys, urinary bladder, and spleen, are 96.2 mGy, 25.4 mGy, and 16.8 mGy, respectively. These radiation doses are for Gallium Ga 68 Gozetotide Injection alone. If CT or a transmission source are used for attenuation correction, the radiation dose will increase by an amount that varies by technique. Table 2: Estimated Radiation Absorbed Dose per Injected Activity in Selected Organs and Tissues of Adults after Intravenous Administration of Gallium Ga 68 Gozetotide Injection Organ Absorbed dose (mGy/MBq) Mean SD Adrenals 0.0156 0.0014 Brain 0.0104 0.0011 Breasts 0.0103 0.0011 Gallbladder 0.0157 0.0012 Lower Colon 0.0134 0.0009 Small Intestine 0.014 0.002 Stomach 0.0129 0.0008 Heart 0.012 0.0009 Kidneys 0.3714 0.0922 Liver 0.0409 0.0076 Lungs 0.0111 0.0007 Muscle 0.0103 0.0003 Pancreas 0.0147 0.0009 Red Marrow 0.0114 0.0016 Skin 0.0091 0.0003 Spleen 0.065 0.018 Testes 0.0111 0.0006 Thymus 0.0105 0.0006 Thyroid 0.0104 0.0006 Urinary Bladder 0.0982 0.0286 Total Body 0.0143 0.0013 Effective Dose (mSv/MBq) 0.0169 0.0015 2.1 Radiation Safety - Drug Handling After reconstitution and radiolabeling of ILLUCCIX, the vial contains Gallium Ga 68 Gozetotide Injection. Handle Gallium Ga 68 Gozetotide Injection with appropriate safety measures to minimize radiation exposure [ see Warnings and Precautions ( 5.2 ) ]. Use waterproof gloves, effective radiation shielding, and other appropriate safety measures when preparing and handling Gallium Ga 68 Gozetotide Injection. Radiopharmaceuticals should be used by or under the control of physicians who are qualified by specific training and experience in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides. 2.2 Recommended Dosage and Administration Instructions Recommended Dosage In adults, the recommended amount of radioactivity to be administered for PET is 111 MBq to 259 MBq (3 mCi to 7 mCi) administered as an intravenous bolus injection. Administration Use aseptic technique and radiation shielding when withdrawing and administering Gallium Ga 68 Gozetotide Injection. Calculate the necessary volume to administer based on calibration time and required dose. Inspect Gallium Ga 68 Gozetotide Injection visually for particulate matter and discoloration before administration. Only use solutions that are clear, colorless or at most slightly yellow, and without visible particles. Gallium Ga 68 Gozetotide Injection may be diluted with sterile 0.9% Sodium Chloride Injection, USP. Assay the final dose in a dose calibrator immediately before administration to the patient. After injection of Gallium Ga 68 Gozetotide Injection, administer an intravenous flush of sterile 0.9% Sodium Chloride Injection, USP to ensure full delivery of the dose. Dispose of any unused drug in a safe manner in compliance with applicable regulations. Unless contraindicated, a diuretic expected to act within the uptake time period may be administered at the time of radiotracer injection to potentially decrease artifact from radiotracer accumulation in the urinary bladder and ureters. 2.3 Patient Preparation Prior to PET Imaging Instruct patients to drink a sufficient amount of water to ensure adequate hydration prior to administration of Gallium Ga 68 Gozetotide Injection and to continue to drink and void frequently following administration to reduce radiation exposure, particularly during the first hour after administration [see Warnings and Precautions ( 5.2 )] . 2.4 Drug Preparation ILLUCCIX is supplied as a 3-vial kit in two different configurations [ see Dosage Forms and Strengths (3) ] for preparation of Gallium Ga 68 Gozetotide Injection with eluate from one of the following (see below for specific instructions for use with each Ga 68 source): Cyclotron produced via GE FASTlab TM (Configuration A) Eckert & Ziegler (EZAG) GalliaPharm ® Germanium 68/Gallium 68 (Ge 68/Ga 68) generator (Configuration A) IRE Galli Eo ® Ge 68/Ga 68 generator (Configuration B) The Ge 68/Ga 68 generators and cyclotron are not supplied with ILLUCCIX. Components of ILLUCCIX include: Vial 1 (Gozetotide Vial) contains 25 mcg of gozetotide and 10 mcg of D-mannose (stabilizer) as a lyophilized powder. Vial 2 (Acetate Buffer Vial) contains 150 mg anhydrous sodium acetate in HCl buffer. Vial 3 (Sterile Vacuumed Reaction Vial) is a sterile, evacuated vial that serves as the collection vial for Ga 68 chloride and radiolabeling reaction. Prepare Gallium Ga 68 Gozetotide Injection according to the following aseptic procedure: Before use, remove the ILLUCCIX kit containing all three components from the refrigerator and allow the kit to reach room temperature for 1 hour. Use suitable shielding to reduce radiation exposure. Wear waterproof gloves. If Ga 68 is generator produced, test the Ga 68 chloride eluate for Ge 68 breakthrough weekly by a suitable method according to manufacturer recommendations. Ge 68 breakthrough and other gamma emitting radionuclides should meet the specifications (≤0.001%) provided by the manufacturer. If Ga 68 is cyclotron produced, test for Ga 66 and Ga 67 (with specification of ≤2% combined total) when a new lot of Zn 68 is introduced for manufacturing. Place a "radioactive" label on Vial 3 (Sterile Vacuumed Reaction Vial) with product name, lot number and date. Remove the vial cap from Vial 1, Vial 2 and Vial 3. Swab the top of each vial with alcohol to disinfect the surface and allow the top of each vial to dry. Note that to minimize any potential metallic contamination, the shortest possible needle should be used for the transfer of the gallium solution from the generator. The needle should be clean and dilute acid resistant. Use only plastic syringes for preparation and administration. Do not use syringes with rubber plungers. Note that prior to use of any vial, confirm the correct vial is being used by a visual check of the vial label. Follow the specific reconstitution procedure below, dependent on Ga 68 source. Then continue with the dilution and radiosynthesis procedure below. Preparation with Cyclotron Produced Ga 68 via GE FASTlab Collection of Gallium Ga 68 Chloride After purification by the FASTlab, the Ga 68 chloride solution is passed through a sterile filter and into the cassette product vial automatically by the FASTlab. Pierce Vial 3 (Sterile Vacuumed Reaction Vial) with a sterile needle connected to a 0.2 micron sterile vented filter (not supplied) to maintain atmospheric pressure within the vial during the reconstitution process. Aseptically transfer 5 mL of Ga 68 chloride solution into Vial 3. Reconstitution and Radiolabeling Reaction Procedure Insert a sterile 10 mL syringe with a needle into Vial 2 (Acetate Buffer Vial Configuration A) and draw up the contents of the vial (target 2.5 mL). Inject the contents of the 10 mL syringe into Vial 1 (Gozetotide Vial). Gently swirl Vial 1 to ensure the product is thoroughly dissolved. Insert a sterile 10 mL syringe with a needle into Vial 1 containing the dissolved gozetotide and draw up the entire contents of the vial. Transfer the contents of the 10 mL syringe to Vial 3 (Sterile Vacuumed Reaction Vial) containing the Ga 68 chloride. Wait for 5 minutes for radiolabeling to take place at ambient temperature (25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F)). Assay the whole vial containing the Gallium Ga 68 Gozetotide Injection for total radioactivity using a dose calibrator, calculate the radioactivity concentration and record the result. Perform the quality control of Gallium Ga 68 Gozetotide Injection according to the recommended methods in the Subsection 2.5 Specifications and Quality Control. Prior to use, visually inspect the solution behind a shielded screen for radioprotection purposes. Only use solutions that are clear without visible particles. Keep the vial containing the Gallium Ga 68 Gozetotide Injection upright in a radio-protective shield container at ambient temperature until use. After reconstitution and addition of Ga 68 chloride to the kit components in the reaction Vial 3, use Gallium Ga 68 Gozetotide Injection within 4 hours. The final volume of the Gallium Ga 68 Gozetotide Injection is 7.5 mL. Preparation with Eckert & Ziegler GalliaPharm Generator Collection of Gallium Ga 68 Chloride Prepare a syringe containing 5 mL of sterile ultrapure 0.1 M HCl provided with the GalliaPharm Generator for elution. Pierce Vial 3 (Sterile Vacuumed Reaction Vial) with a sterile needle connected to a 0.2 micron sterile vented filter (not supplied) to maintain atmospheric pressure within the vial during the reconstitution process. Connect the male luer of the outlet line of the GalliaPharm generator to a sterile needle. Connect Vial 3 directly to the outlet line of the GalliaPharm generator by pushing the needle through the rubber septum and place the vial in a radiation shielded container. Elute the generator directly with the 5 mL 0.1 M HCl from step 1 into Vial 3 according to the instructions for use of the GalliaPharm generator that are supplied by Eckert & Ziegler. Perform the elution manually or by means of a pump. Collect 5 mL of eluate. At the end of the elution, disconnect the generator from Vial 3 by removing the needle from the rubber septum. Reconstitution and Radiolabeling Reaction Procedure Insert a sterile 10 mL syringe with a needle into Vial 2 (Acetate Buffer Vial Configuration A) and draw up the contents of the vial (target 2.5 mL). Inject the contents of the 10 mL syringe into Vial 1 (Gozetotide Vial). Gently swirl Vial 1 to ensure the product is thoroughly dissolved. Insert a sterile 10 mL syringe with a needle into Vial 1 containing the dissolved gozetotide and draw up the entire contents of the vial. Transfer the contents of the 10 mL syringe to Vial 3 (Sterile Vacuumed Reaction Vial) containing the Ga 68 chloride. Wait for 5 minutes for radiolabeling to take place at ambient temperature (25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F)). Assay the whole vial containing the Gallium Ga 68 Gozetotide Injection for total radioactivity using a dose calibrator, calculate the radioactivity concentration and record the result. Perform the quality control of Gallium Ga 68 Gozetotide Injection according to the recommended methods in the Subsection 2.5 Specifications and Quality Control. Prior to use, visually inspect the solution behind a shielded screen for radioprotection purposes. Only use solutions that are clear without visible particles. Keep the vial containing the Gallium Ga 68 Gozetotide Injection upright in a radio-protective shield container at ambient temperature until use. After reconstitution and addition of Ga 68 chloride to the kit components in the reaction Vial 3, use Gallium Ga 68 Gozetotide Injection within 4 hours. The final volume of the Gallium Ga 68 Gozetotide Injection is 7.5 mL. Preparation with IRE Galli Eo Generator Collection of Gallium Ga 68 Chloride Connect the male luer of the outlet line of the Galli Eo generator to a sterile needle. Elute the generator directly into Vial 3 (Sterile Vacuumed Reaction Vial) according to the instructions for use of the Galli Eo generator that are supplied by IRE. Collect 1.1 mL of eluate. At the end of the elution, disconnect the generator from Vial 3 by removing the needle from the rubber septum. Reconstitution and Radiolabeling Reaction Procedure Insert a sterile 10 mL syringe with a needle into Vial 2 (Acetate Buffer Vial Configuration B) and draw up the contents of the vial (target 6.4 mL). Inject the contents of the 10 mL syringe into Vial 1 (Gozetotide Vial). Gently swirl Vial 1 to ensure the product is thoroughly dissolved. Insert a sterile 10 mL syringe with a needle into Vial 1 containing the dissolved gozetotide and draw up the entire contents of the vial. Transfer the contents of the 10 mL syringe to Vial 3 (Sterile Vacuumed Reaction Vial) containing the Ga 68 chloride. Wait for 5 minutes for radiolabeling to take place at ambient temperature (25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F)). Assay the whole vial containing the Gallium Ga 68 Gozetotide Injection for total radioactivity using a dose calibrator, calculate the radioactivity concentration and record the result. Perform the quality control of Gallium Ga 68 Gozetotide Injection according to the recommended methods in the Subsection 2.5 Specifications and Quality Control. Prior to use, visually inspect the solution behind a shielded screen for radioprotection purposes. Only use solutions that are clear without visible particles. Keep the vial containing the Gallium Ga 68 Gozetotide Injection upright in a radio-protective shield container at ambient temperature until use. After reconstitution and addition of Ga 68 chloride to the kit components in the reaction Vial 3, use Gallium Ga 68 Gozetotide Injection within 4 hours. The final volume of the Gallium Ga 68 Gozetotide Injection is 7.5 mL. Flow diagrams are provided for the radiosynthetic process to be followed at the radiopharmacy site for: ILLUCCIX Configuration "A" when using Ga 68 prepared by cyclotron ( Figure 1 ) or ILLUCCIX Configurations "A" or "B" when using an indicated GMP-grade EZAG GalliaPharm Ge 68/Ga 68 Generator ( Figure 2 ) or IRE Galli Eo Ge 68/Ga 68 Generator ( Figure 3 ). Figure 1: Preparation with Cyclotron Produced Ga 68 via GE FASTlab Note: Ga 68 from GE FASTlab is aseptically transferred into the Sterile Vacuumed Reaction Vial. Use "Configuration A" with cyclotron produced Ga 68 via GE FASTlab [ see How Supplied/Storage and Handling ( 16 )] . Figure 2: Preparation with Eckert & Ziegler GalliaPharm Generator Note: Use "Configuration A" with EZAG GalliaPharm Ge 68/Ga 68 generator [ see How Supplied/Storage and Handling ( 16 )] . Figure 3: Preparation with IRE Galli Eo Generator Note: Use "Configuration B" with IRE Galli Eo Ge 68/Ga 68 generator [ see How Supplied/Storage and Handling ( 16 )] . Figure 1 Figure 2 Figure 3 2.5 Specifications and Quality Control Perform the quality controls in Table 1 behind a lead glass shield for radioprotection purposes. Table 1: Specifications for the Radiolabeled Imaging Product (Gallium Ga 68 Gozetotide Injection) Test Analytical method Acceptance criteria Appearance Visual examination Colorless to slightly yellow solution Free from visible particles pH pH-meter or pH-strips 4.0 to 5.0 Radiochemical purity Content of gallium Ga 68 gozetotide Content of free and colloidal Ga 68 Instant thin-layer chromatography, silica gel (iTLC SG); See methods below ≥95% ≤5% Perform one of the following: Cutting Technique Pour ammonium acetate 1 M/methanol (1/1 V/V) solution to a depth of 3 mm to 4 mm in the developing chamber, cover the chamber and allow it to equilibrate. Draw a pencil line at 1 cm from the bottom of the iTLC strip, and a dotted line 5 cm from the pencil line. Apply a drop of gallium Ga 68 gozetotide at the center of the pencil line. Place the iTLC strip in the developing chamber and allow it to develop for a distance of 10 cm from the point of application. Cut the iTLC strip following the dotted line and measure each piece with the radioactivity dose calibrator. Calculate the quantity (in percent) of gallium Ga 68 gozetotide in the solution using the formula: % Gallium Ga 68 gozetotide=(Activity top piece)/(Activity bottom piece+Activity top piece) ×100 Scanning Technique Pour ammonium acetate 1 M/methanol (1/1 V/V) solution to a depth of 3 mm to 4 mm in the developing chamber, cover the chamber and allow it to equilibrate. Draw a pencil line at 1 cm from the bottom of the iTLC strip and apply a drop of gallium Ga 68 gozetotide at the center of the pencil line. Place the iTLC strip in the developing chamber and allow it to develop for a distance of 10 cm from the point of application. Scan the iTLC with a radiometric iTLC scanner. Calculate the quantity (in percent) of gallium Ga 68 gozetotide in the solution by integration of the peaks on the chromatogram. The retention factor (Rf) specifications are: Free and colloidal Ga 68 species, Rf = 0 to 0.1, Gallium Ga 68 gozetotide, Rf = 0.6 to 1. 2.6 Image Acquisition Position the patient supine with arms above the head. Begin PET scanning 50 minutes to 100 minutes after the intravenous administration of Gallium Ga 68 Gozetotide Injection. Patients should void immediately prior to image acquisition and image acquisition should begin at the proximal thighs and proceed cranially to the skull base or skull vertex. Adapt imaging technique according to the equipment used and patient characteristics in order to obtain the best image quality possible. 2.7 Image Interpretation Gallium Ga 68 gozetotide binds to PSMA. Based on the intensity of the signals, PET images obtained using gallium Ga 68 gozetotide indicate the presence of PSMA in tissues. Imaging Prior to Initial Definitive Therapy or for Biochemical Recurrence Lesions should be considered suspicious if uptake is greater than physiologic uptake in that tissue or greater than adjacent background if no physiologic uptake is expected. Tumors that do not express PSMA will not be visualized. Increased uptake in tumors is not specific for prostate cancer [ see Warnings and Precautions ( 5.1 ) ]. Imaging to Select Patients for PSMA-Directed Therapy For instructions on patient selection, refer to the prescribing information of the PSMA-directed therapeutic product. 2.8 Radiation Dosimetry Estimated radiation absorbed doses per injected activity for organs and tissues of adult male patients following an intravenous bolus of Gallium Ga 68 Gozetotide Injection are shown in Table 2 . The effective radiation dose resulting from the administration of 259 MBq (7 mCi) is about 4.4 mSv. The radiation doses for this administered dose to the critical organs, which are the kidneys, urinary bladder, and spleen, are 96.2 mGy, 25.4 mGy, and 16.8 mGy, respectively. These radiation doses are for Gallium Ga 68 Gozetotide Injection alone. If CT or a transmission source are used for attenuation correction, the radiation dose will increase by an amount that varies by technique. Table 2: Estimated Radiation Absorbed Dose per Injected Activity in Selected Organs and Tissues of Adults after Intravenous Administration of Gallium Ga 68 Gozetotide Injection Organ Absorbed dose (mGy/MBq) Mean SD Adrenals 0.0156 0.0014 Brain 0.0104 0.0011 Breasts 0.0103 0.0011 Gallbladder 0.0157 0.0012 Lower Colon 0.0134 0.0009 Small Intestine 0.014 0.002 Stomach 0.0129 0.0008 Heart 0.012 0.0009 Kidneys 0.3714 0.0922 Liver 0.0409 0.0076 Lungs 0.0111 0.0007 Muscle 0.0103 0.0003 Pancreas 0.0147 0.0009 Red Marrow 0.0114 0.0016 Skin 0.0091 0.0003 Spleen 0.065 0.018 Testes 0.0111 0.0006 Thymus 0.0105 0.0006 Thyroid 0.0104 0.0006 Urinary Bladder 0.0982 0.0286 Total Body 0.0143 0.0013 Effective Dose (mSv/MBq) 0.0169 0.0015

4 CONTRAINDICATIONS None None ( 4 )

5 WARNINGS AND PRECAUTIONS Risk for Misinterpretation: Gallium Ga 68 gozetotide uptake can be seen in a variety of tumor types and in non-malignant processes. Interpretation of ILLUCCIX PET imaging with histopathology and/or other diagnostic procedures is recommended. ( 5.1 ) Radiation Risks: Ensure safe handling to protect patients and health care providers from unintentional radiation exposure. ( 2.1 , 5.2 ) 5.1 Risk for Misinterpretation Image interpretation errors can occur with ILLUCCIX PET. A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer. Gallium Ga 68 gozetotide uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes such as Paget's disease, fibrous dysplasia, and osteophytosis. Clinical correlation, which may include histopathological evaluation of the suspected prostate cancer site, is recommended. The performance of ILLUCCIX for imaging of biochemically recurrent prostate cancer seems to be affected by serum PSA levels and by site of disease. The performance of ILLUCCIX for imaging of metastatic pelvic lymph nodes prior to initial definitive therapy seems to be affected by Gleason score [ see Clinical Studies (14.1 , 14.2) ] . 5.2 Radiation Risks Gallium Ga 68 gozetotide contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Ensure safe handling to minimize radiation exposure to the patient and health care providers. Advise patients to hydrate before and after administration and to void frequently after administration [see Dosage and Administration ( 2.1 , 2.3 )] . 5.1 Risk for Misinterpretation Image interpretation errors can occur with ILLUCCIX PET. A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer. Gallium Ga 68 gozetotide uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes such as Paget's disease, fibrous dysplasia, and osteophytosis. Clinical correlation, which may include histopathological evaluation of the suspected prostate cancer site, is recommended. The performance of ILLUCCIX for imaging of biochemically recurrent prostate cancer seems to be affected by serum PSA levels and by site of disease. The performance of ILLUCCIX for imaging of metastatic pelvic lymph nodes prior to initial definitive therapy seems to be affected by Gleason score [ see Clinical Studies (14.1 , 14.2) ] . 5.2 Radiation Risks Gallium Ga 68 gozetotide contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Ensure safe handling to minimize radiation exposure to the patient and health care providers. Advise patients to hydrate before and after administration and to void frequently after administration [see Dosage and Administration ( 2.1 , 2.3 )] .

7 DRUG INTERACTIONS Androgen deprivation therapy and other therapies targeting the androgen pathway Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, can result in changes in uptake of gallium Ga 68 gozetotide in prostate cancer. The effect of these therapies on performance of gallium Ga 68 gozetotide PET has not been established.

6 ADVERSE REACTIONS The most commonly reported adverse reactions (incidence ≥ 0.5%) include fatigue, nausea, constipation, and vomiting. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Telix Pharmaceuticals (US) Inc. at 1-844-455-8638 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of ILLUCCIX has been established based on three prospective studies of gallium Ga 68 gozetotide in patients with prostate cancer (i.e., Studies 1, 2, and 3). Adverse reactions from these studies are reported below. In Studies 1 and 2 using another formulation of gallium Ga 68 gozetotide injection, 960 patients received one dose of gallium Ga 68 gozetotide intravenously with the amount (mean ± SD) of radioactivity 188.7 ± 40.7 MBq (5.1 ± 1.1 mCi) [ see Clinical Studies ( 14.1 , 14.2 ) ]. The most commonly reported adverse reactions were nausea, diarrhea, and dizziness, occurring at a rate of <1%. In a randomized, multicenter, open-label clinical study (NCT03511664, referred to as Study 3) in which gallium Ga 68 gozetotide was used to identify PSMA-positive patients on PET imaging to determine eligibility for PSMA-directed therapy, 1,003 patients with progressive metastatic castration-resistant prostate cancer (mCRPC) received one dose of gallium Ga 68 gozetotide intravenously with the amount of radioactivity 167.1 ± 23.1 MBq (4.52 ± 0.62 mCi). Patients were males with median age of 70 years (range, 40 to 94 years), were White (87%), Black or African American (7%), or Asian (2.4%), and had median baseline PSA levels of 74 ng/mL (range, 0 to 8,995 ng/mL). Adverse reactions occurring at ≥ 0.5% in patients with metastatic prostate cancer who received gallium Ga 68 gozetotide injection in Study 3 are presented in Table 3. Table 3 : Adverse Reactions (≥ 0.5%) in Patients with Metastatic Prostate Cancer Who Received Gallium Ga 68 Gozetotide Injection in Study 3 Adverse Reaction Gallium Ga 68 Gozetotide Injection N = 1,003 n (%) General disorders Fatigue 12 (1.2) Gastrointestinal disorders Nausea 8 (0.8) Constipation 5 (0.5) Vomiting 5 (0.5) Adverse reactions occurring at a rate of < 0.5% in the study were diarrhea, dry mouth, injection site reactions, including injection site hematoma and injection site warmth and chills. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of ILLUCCIX. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. General Disorders and Administration Site Conditions : injection site pain.

8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary ILLUCCIX is not indicated for use in females. There are no available data with gallium Ga 68 gozetotide injection use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. All radiopharmaceuticals, including ILLUCCIX, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose. Animal reproduction studies have not been conducted with gallium Ga 68 gozetotide. 8.2 Lactation Risk Summary ILLUCCIX is not indicated for use in females. There are no data on the presence of gallium Ga 68 gozetotide in human milk, the effect on the breastfed infant, or the effect on milk production. 8.4 Pediatric Use The safety and effectiveness of gallium Ga 68 gozetotide in pediatric patients have not been established. 8.5 Geriatric Use The efficacy of gallium Ga 68 gozetotide PET in geriatric patients with prostate cancer is based on data from three prospective studies. Of the total number of patients in Studies 1 and 2 [see Clinical Studies (14.1 , 14.2) ] , 691 of 960 (72%) patients were 65 years of age and older while 195 (20%) were 75 years of age and older. Of the total number of patients in Study 3 [ see Adverse Reactions (6.1) ], 752 of 1,003 (75%) patients were 65 years of age and older while 284 (28%) were 75 years of age and older. The efficacy and safety profiles of gallium Ga 68 gozetotide appear similar in younger adult and geriatric patients with prostate cancer and other reported clinical experience has not identified differences in responses between the elderly and younger adult patients. 8.1 Pregnancy Risk Summary ILLUCCIX is not indicated for use in females. There are no available data with gallium Ga 68 gozetotide injection use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. All radiopharmaceuticals, including ILLUCCIX, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose. Animal reproduction studies have not been conducted with gallium Ga 68 gozetotide. 8.2 Lactation Risk Summary ILLUCCIX is not indicated for use in females. There are no data on the presence of gallium Ga 68 gozetotide in human milk, the effect on the breastfed infant, or the effect on milk production. 8.4 Pediatric Use The safety and effectiveness of gallium Ga 68 gozetotide in pediatric patients have not been established. 8.5 Geriatric Use The efficacy of gallium Ga 68 gozetotide PET in geriatric patients with prostate cancer is based on data from three prospective studies. Of the total number of patients in Studies 1 and 2 [see Clinical Studies (14.1 , 14.2) ] , 691 of 960 (72%) patients were 65 years of age and older while 195 (20%) were 75 years of age and older. Of the total number of patients in Study 3 [ see Adverse Reactions (6.1) ], 752 of 1,003 (75%) patients were 65 years of age and older while 284 (28%) were 75 years of age and older. The efficacy and safety profiles of gallium Ga 68 gozetotide appear similar in younger adult and geriatric patients with prostate cancer and other reported clinical experience has not identified differences in responses between the elderly and younger adult patients.